scholarly journals A Nomogram to Predict Long-Term Survival Outcomes of Patients Who Undergo Pneumonectomy for Non-small Cell Lung Cancer With Stage I-IIIB

2021 ◽  
Vol 8 ◽  
Author(s):  
Lei-Lei Wu ◽  
Wu-Tao Chen ◽  
Xuan Liu ◽  
Wen-Mei Jiang ◽  
Yang-Yu Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Risk Groups ◽  
Small Cell ◽  
Low Risk ◽  
Small Cell Lung ◽  
Risk Patients ◽  
Nsclc Patients

Background: In this study, we aim to establish a nomogram to predict the prognosis of non-small cell lung cancer (NSCLC) patients with stage I-IIIB disease after pneumonectomy.Methods: Patients selected from the Surveillance, Epidemiology, and End Results (SEER, N = 2,373) database were divided into two cohorts, namely a training cohort (SEER-T, N = 1,196) and an internal validation cohort (SEER-V, N = 1,177). Two cohorts were dichotomized into low- and high-risk subgroups by the optimal risk prognostic score (PS). The model was validated by indices of concordance (C-index) and calibration plots. Kaplan-Meier analysis and the log-rank tests were used to compare survival curves between the groups. The primary observational endpoint was cancer-specific survival (CSS).Results: The nomogram comprised six factors as independent prognostic indictors; it significantly distinguished between low- and high-risk groups (all P < 0.05). The unadjusted 5-year CSS rates of high-risk and low-risk groups were 33 and 60% (SEER-T), 34 and 55% (SEER-V), respectively; the C-index of this nomogram in predicting CSS was higher than that in the 8th TNM staging system (SEER-T, 0.629 vs. 0.584, P < 0.001; SEER-V, 0.609 vs. 0.576, P < 0.001). In addition, the PS might be a significant negative indictor on CSS of patients with white patients [unadjusted hazard ration (HR) 1.008, P < 0.001], black patients (unadjusted HR 1.007, P < 0.001), and Asian or Pacific Islander (unadjusted HR 1.008, P = 0.008). In cases with squamous cell carcinoma (unadjusted HR 1.008, P < 0.001) or adenocarcinoma (unadjusted HR 1.008, P < 0.001), PS also might be a significant risk factor.Conclusions: For post-pneumonectomy NSCLC patients, the nomogram may predict their survival with acceptable accuracy and further distinguish high-risk patients from low-risk patients.

scholarly journals Identification and Validation of an Immune and Ferroptosis-Combined Index for Non–Small Cell Lung Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Yang Teng ◽  
Bo Wang ◽  
Desi Shang ◽  
Ning Yang
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Risk Score ◽  
Cell Lung Cancer ◽  
Risk Group ◽  
Risk Groups ◽  
Small Cell ◽  
Low Risk ◽  
Small Cell Lung

Background: Non–small cell lung cancer (NSCLC) is among the major health problems around the world. Reliable biomarkers for NSCLC are still needed in clinical practice. We aimed to develop a novel ferroptosis- and immune-based index for NSCLC.Methods: The training and testing datasets were obtained from TCGA and GEO databases, respectively. Immune- and ferroptosis-related genes were identified and used to establish a prognostic model. Then, the prognostic and therapeutic potential of the established index was evaluated.Results: Intimate interaction of immune genes with ferroptosis genes was observed. A total of 32 prognosis-related signatures were selected to develop a predictive model for NSCLC using LASSO Cox regression. Patients were classified into the high- and low-risk group based on the risk score. Patients in the low-risk group have better OS in contrast with that in the high-risk group in independent verification datasets. Besides, patients with a high risk score have shorter OS in all subgroups (T, N, and M0 subgroups) and pathological stages (stage I, II, and III). The risk score was positively associated with Immune Score, Stromal Score, and Ferroptosis Score in TCGA and GEO cohorts. A differential immune cell infiltration between the high-risk and the low-risk groups was also observed. Finally, we explored the significance of our model in tumor-related pathways, and different enrichment levels in the therapeutic pathway were observed between the high- and low-risk groups.Conclusion: The present study developed an immune and ferroptosis-combined index for the prognosis of NSCLC.

scholarly journals OUTCOMES FOLLOWING LIMITED LUNG RESECTION FOR NON-SMALL CELL LUNG CANCER (NSCLC) IN HIGH RISK PATIENTS

CHEST Journal ◽  
2005 ◽  
Vol 128 (4) ◽  
pp. 140S
Author(s):  
Lisa M. Guirguis ◽  
Eric C.C. Feliberti ◽  
Nicole Tsai ◽  
Frederic W. Grannis
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Lung Resection ◽  
Small Cell ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

Robotic Brachytherapy and Sublobar Resection for T1 Non-Small Cell Lung Cancer in High-Risk Patients

2010 ◽  
Vol 89 (2) ◽  
pp. 360-367 ◽  
Author(s):  
Justin D. Blasberg ◽  
Scott J. Belsley ◽  
Gary S. Schwartz ◽  
Andrew Evans ◽  
Iddo Wernick ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Sublobar Resection ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

Comparison between sublobar resection and 125Iodine brachytherapy after sublobar resection in high-risk patients with Stage I non–small-cell lung cancer

Surgery ◽  
2003 ◽  
Vol 134 (4) ◽  
pp. 691-697 ◽  
Author(s):  
Ricardo Santos ◽  
Athanasios Colonias ◽  
David Parda ◽  
Mark Trombetta ◽  
Richard H Maley ◽  
...  
Keyword(s):  
Lung Cancer ◽  
High Risk ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Sublobar Resection ◽  
Small Cell Lung ◽  
High Risk Patients ◽  
Risk Patients

Construction of a Prognostic Signature of Autophagy-Related lncRNAs in Non-Small Cell Lung Cancer

2021 ◽  
Author(s):  
Xinyang Zhang ◽  
Yu Cao ◽  
Li Chen
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Value At Risk ◽  
Prognostic Model ◽  
Risk Groups ◽  
Small Cell ◽  
Low Risk ◽  
Prognostic Signature ◽  
Small Cell Lung

Abstract Background: Autophagy inhibits tumorigenesis by limiting inflammation, LncRNA regulates gene expression levels in the form of RNA at various levels, so both of them are closely related to the occurrence and development of tumors.Methods: 232 autophagy-related genes were used to construct a co-expression network to extract autophagy-related lncRNAs. A prognostic signature was constructed by multivariate regression analysis. Kyoto Encyclopedia of Genes and Genomes (KEGG) was applied to analyze pathway enrichment in cancer pathways. Immunoinfiltration analysis was used to analyze the relationship between the prognostic model and the tumor.Results: Nine autophagy-related lncRNAs were used to construct a prognostic model for non-small cell lung cancer. The median value of the value at risk was used to distinguish between the high and low risk groups, and the low-risk group had better survival. Because the KEGG pathway analysis showed that the prognostic model was enriched in some immune pathways, further exploration of immune infiltration was conducted and it was found that the prognostic model did play a unique role in the immune microenvironment. And the prognostic model was associated with clinical factors.Conclusion: The prognostic model of autophagy-related lncRNAs constructed by us can predict the prognosis of non-small cell lung cancer.

scholarly journals P14.97 High risk of venous thromboembolism in patients with brain metastases from non-small cell lung cancer

2019 ◽  
Vol 21 (Supplement_3) ◽  
pp. iii91-iii91
Author(s):  
P Mir Seyed Nazari ◽  
C Ay ◽  
A Steindl ◽  
B Gatterbauer ◽  
J M Frischer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Venous Thromboembolism ◽  
High Risk ◽  
Brain Metastases ◽  
Small Cell Lung Cancer ◽  
Cell Carcinoma ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nsclc Patients

Abstract BACKGROUND Venous thromboembolism (VTE) is a common complication in patients with cancer. In general, patients with metastatic disease are at highest risk. Lung cancer belong to those tumor entities with a particularly high risk of VTE, ranging between 3–13.8%. However, little is known about the VTE rate in lung cancer patients with brain metastases. MATERIAL AND METHODS Our study was conducted in the framework of the Vienna Brain Metastasis Registry. Clinical data and VTE events during the course of the disease were recorded via retrospective chart review. In this analysis, non-small cell lung cancer (NSCLC) patients with a resection of brain metastases at the Medical University of Vienna between 2006 and 2010 were included. RESULTS In total, 69 NSCLC patients with brain metastases were analyzed. Overall, 69.6% (48/69) patients had an adenocarcinoma, 13% (9/69) a squamous cell carcinoma, 8.7% (6/69) a large cell carcinoma and 8.7% (6/69) other primary tumor histologies. After cancer diagnosis, 20.3% (14/69) patients developed VTE during the course of the disease. Of those, 85.7% (12/14) thromboembolic events occurred after the diagnosis of brain metastases. CONCLUSION Based on our data, patients with brain metastases from NSCLC have a very high VTE risk. Further investigations are needed in order to identify patients with distinct VTE risk profiles. Patients at high risk might potentially benefit from primary thromboprophylaxis over the high risk of intracerebral bleeding.

Sign in / Sign up

Export Citation Format

Share Document